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Summary Amphethinile is a new spindle poison with a novel structure that has shown activity in the L1210,
ADJ/PC6 and Walker carcinoma rodent tumours. In addition the agent appeared to have an improved
therapeutic ratio compared to existing spindle poisons and is well absorbed when administered orally. The
starting dose for the phase I study was 40mgm 2 (1/10th mouse LD10) and further patients were studied at
200, 400, 800 and 1200 mgm2, dose escalation being based on pharmacological monitoring. Significant toxic
effects were seen only at 800 and 1200mgm-2. At these doses patients experienced nausea and vomiting, light
headedness during the infusion and varying degrees of lethargy following therapy. Two of six patients at
800 mgm 2 developed severe pain in the tumour bearing area 1-2h after treatment and one experienced
colicky abdominal pain. At 1200mgm-2 two patients died within 48 h of treatment from what appeared to be
vascular causes. Following these episodes the trial was discontinued. Neutropenia and alopecia occurred in
two patients, one at 800 and one at 1200 mgm 2. These patients achieved the highest drug exposure in terms
of area under the concentration x time curve.
It was not possible to achieve an AUC consistently high enough to produce cytotoxic effects due to the
occurrence of dose limiting toxicities thus amphethinile cannot at present be recommended for phase II testing
by the i.v. route.
The dose escalation scheme based on pharmacological monitoring resulted in a considerable saving in the
duration of the trial. Further evaluation of this methodology is recommended.
Amphethinile (ICI 134154, CRC 82/07) is a novel compound
(Figure 1) which was first synthesised by ICI plc (Alderley
Park, Cheshire) and aroused interest when it was shown to
terminate pregnancy in rats. This effect occurred following
two injections on day 9 of gestation or one on day 10 and
the qualitative appearance of the degenerating implants
suggested that it might be due to cytotoxic damage. The
drug was fully effective both orally and subcutaneously at a
dose of 5mgkg- 1 and produced other toxic effects at a dose
of 25mgkg-1, suggesting a therapeutic ratio of - 5:1.
Experiments with HeLa cells indicated that amphethinile was
acting as a spindle poison and in similar experiments on
pregnant rats vincristine was shown to have a therapeutic
ratio of 2-3:1. These results suggest that amphethinile may
have an improved therapeutic ratio compared to vincristine.
The compound was submitted to the NCI pre-clinical
screen and was shown to be active in L1210, ADJ/PC6 and
the Walker carcinoma but inactive in the TLX/5 and GHS-
Pit tumours.
In view of this pre-clinical activity, the possible improve-
ment in therapeutic ratio compared with existing spindle
poisons and the good oral absorption, the drug was taken
up by the CRC Phase I/II committee for formulation and
pre-clinical toxicology.
Amphethinile was found to be extremely insoluble in
aqueous solution (2.5ppm at 20°C and 6ppm at 37°C).
Moreover the use of polar solvents carries a risk of precipi-
tation of the compound on contact with aqueous solutions,
e.g., blood. In view of this a formulation was developed
using the surfactant Solutol HS15. Solutol is the reaction
product of 12-hydroxystearic acid and ethylene oxide and in
animal experiments appeared to be up to 30 times less
allergenic than the related compound Cremophor EL.
Amphethinile forms a highly stable optically clear microsus-
pension or solubilizate in Solutol which does not precipitate
on dilution. Such a stable formulation occurs at Solutol/
Amphethinile ratios between 5 and 10 and this formulation
was submitted to preclinical toxicology.
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Figure 1 Structure of Amphethinile.
Preclinical toxicology was carried out by BIBRA Ltd.,
Carshalton, Surrey according to CRC Phase I/II Committee
requirements. The LDIO for the acute i.v. schedule was
411 mgm 2 and 1/Oth of this dose was selected as the
starting dose for phase I clinical trials. This dose was shown
to be entirely non-toxic in the rat.
The main acute effect of i.v. administration of high doses
of solutol formulated amphethinile to mice was an imme-
diate catatonic reaction and in some cases death. This was
also found to occur with Solutol alone and was therefore
considered to be a property of the vehicle. The effect could
be avoided by slow i.v. administration over 30 seconds.
Haematological studies showed a rapid fall in the number
of circulating granulocytes, lymphocytes and platelets by day
3 following drug administration. The granulocytes and plate-
lets recovered to normal levels by day 10 but only at the
lowest dose was there definite recovery in the lymphocyte
population by day 28. No effect was seen on the red cells.
Histological examination of the marrow, spleen and lymph
nodes showed moderate necrosis in mice dying within 2 days
of treatment but no changes in mice sacrificed at 14 days.
These changes may be responsible for the slow recovery seen
in the peripheral lymphocyte count.
The major histological changes seen were in the testes.
Germ cell and spermatogonial necrosis occurred at all dose
levels, in severe cases leading to tubular calcification, atro-
phy and interstitial cell hyperplasia. These changes appeared
to be dose related.
A small percentage of the mice dying within two days of
treatment had minimal necrosis of the glandular, squamous
or sub-mucosal areas of the stomach and of the crypt
epithelium cells of the small intestine. No abnormalities were
seen in these areas in mice sacrificed at 14 or 28 days and no
additional changes were detected in any of the remaining
organs examined.
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Patients and methods
The initial phase I clinical trial of amphethinile using an
intermittent i.v. schedule was activated in July 1986. Patients
entered in the trial had solid tumours which had failed
conventional therapy or for whom no such treatment exists.
In addition they were required to have a life expectancy of at
least two months, a World Health Organisation performance
status of 0-2 and normal renal and hepatic function. Patients
with significant co-existing medical conditions were excluded.
The starting dose for the study was 40mgm 2 and it was
planned to enter two patients at each non-toxic dose and at
least six at doses recommended for phase II testing.
The dose escalation scheme used in this study was based
on the proposals outlined by Collins et al. (1986). These
workers noted a close correlation between the area under the
concentration x time curve (AUC) at the LD1O in the
mouse and the AUC at the maximum tolerated dose (MTD)
in man. It was therefore suggested that the AUC at the mouse
LD10 could be used as a target to assist more rapid dose
escalation based on pharmacokinetic measurements at the
initial dose levels in man. The method used in this trial was
a modification of the geometric mean method suggested by
Collins et al. but with a maximum initial escalation of 5n
providing the AUC at the starting dose was <5% of the
target AUC.
Toxicity was graded according to the World Health Orga-
nisation system (Miller et al., 1981).
The protocol was approved by the Christie Hospital
Protocol Review Committee and the South Manchester
Medical Ethical Committee according to normal practice. All
patients entered in the trial gave informed verbal consent.
Pharmacokinetic methods
In order to determine the target AUC for the phase I trial
the pharmacokinetics of amphethinile were determined in 8-
10 week old Paterson BDF1 mice. A preliminary experiment
confirmed that the LDIO for amphethinile in these mice was
similar to that for the MF1 mice used for pre-clinical
toxicology i.e., 400mgm-2. The kinetics were then assessed
at 100, 200 and 400mgm-2 in order to gain data on their
linearity over a range of doses. At each of these doses three
mice were sacrificed at 5, 15, 30 and 60min and 2, 4, 6 and
8h following bolus i.v. injection into the tail vein. Mice were
exsanguinated via a small incision in the lateral canthus. The
serum separated and stored at -20°C prior to assay.
During the phase I study blood samples were obtained at
5, 10, 20, 30, 60 and 90min and 2, 3, 6, 9, 12 and 24h after
drug administration. In addition urine was collected during
the first 24h after dosing, the total volume passed recorded
and a 5ml aliquot stored with the serum samples at -20°C.
A reverse phase HPLC method was developed for the
measurement of amphethinile in the serum and urine. The
extraction procedure was as follows. To each 0.5ml sample
of serum or urine was added 20pg 1-nitro-5-chloro aniline to
act as an internal standard for the assay. Chloroform (8ml)
was then added and the solution mixed by vortexing for
30sec. The precipitate and aqueous phase were removed by
passage through phase separation filters. The resulting chlor-
oform solution was evaporated to dryness and the residue
resuspended in 50p1 methanol prior to injection onto the
column.
HPLC conditions
Column: 5 p ODS hypersil
Mobile phase: 70% methanol/30% water/0.1% phosphoric
acid
Flow rate: 1.25mlmin1
UV absorbance: 305nm
Pump: PYE UNICAM 4010
UV detector: PYE UNICAM 4020
Using this method the lower limit of detection of
amphethinile was 0.1 pgml (100ngml).
Pharmacokinetic analysis
The data from this study were analysed using a non-iterative
computer programme. Area under the curve to infinity was
calculated from the expression:
AUC=A/la +B/
Where A and B are the intercepts on the concentration axis
and a and 3 the elimination rate constants calculated by the
computer programme.
Results
Pharmacokinetics of amphethinile in mice
The serum decay of total chloroform extractable amphethi-
nile in mice conformed to a two compartment model at each
of the three dose levels studied. The AUC at 100mgm-2
was 34pg-1h-1, at 200mgm 2 was 95pgI 1h 1 and at
400 mgm-2 was 313MgI -1h-1. Thus for each doubling of
dose there was a threefold increase in AUC, indicating a
degree of non-linearity in the kinetics. However this was not
reflected in a lengthening of the elimination half life or a
decrease in the clearance rate with increasing dose (Table I;
Figure 2). In addition to the parent compound chromatogra-
phy revealed an additional peak that eluted before the
amphethinile and probably represents a polar hepatic meta-
bolite (Figure 3). The quantity of this metabolite formed
Table I Pharmacokinetic parameters of amphethinile in mice
VC VD VDSS VPC
KE K2> I K2<1 It It It It
LD1O 1.2 8.2 10.3 0.01 0.01 0.01 0.01
LD5 1.1 2.1 2.0 0.01 0.03 0.03 0.01
LD2.5 0.9 1.4 2.2 0.02 0.08 0.07 0.04
TJ/2a TJ/2# AUC Cl AUC Metabolite
h h pgl-l h- mlmin-C Ul 1h-1
LD1O 0.03 1.34 313 0.17 233
LD5 0.14 1.36 95 0.31 532
LD2.5 0.15 2.06 34 0.48 1019
KE: elimination rate constant; K2> 1: rate constant governing
transfer from peripheral to central compartment; K2<1: rate con-
stant governing from central to peripheral compartment; VC:
volume of the central compartment; VDarea: volume of distribution
at time zero; VDSS: volume of distribution at steady state; VPC:
volume of the peripheral compartment; Tl/2a: half life of the a
(distribution) phase; T1/2,B: half life of the ,B (elimination) phase;
AUC: area under the concentration/time curve; Cl: clearance.
Onn _
C
0 0
Time (hours)
Figure 2 Plasma decay curves of amphethinile in mice at 100,
200 and 400mgm-2. Values represent the mean of 3 mice at
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Figure 3 Chromatogram of (1) amphethinile metabolite, (2) 2-
nitro-5-chloro aniline, (3) amphethinile.
increased by a factor of two with each doubling of the dose
(Figure 4).
The AUC at the LD1O in the mouse was therefore
313 pgI1 h- and this was selected as the target AUC for
the phase I trial.
Pharmacokinetics of amphethinile in man
Amphethinile could not be measured at the starting dose
40mgm-2. At subsequent doses, 200, 400, 800 and
1200mgm2, the experimental data fitted a two compart-
ment model. However there was an - 4-fold increase in
AUC for each doubling of the dose and this was reflected in
a progressive rise in elimination half life and a fall in
clearance with increasing dose (Table II, Figure 5). In
0
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Figure 4 Plasma decay curves of the amphethinile metabolite in
mice at 100 (+), 200 (x) and 400 (O)mgm-2. The units of
concentration are arbitrary and are derived from the chromato-
gram peak area.
common with the mouse experiments an additional unidenti-
fied peak was seen that eluted before the amphethinile peak.
However, there was evidence that the metabolism of
amphethinile was saturable in man with the production of
metabolite rising to a plateau and remaining constant for
several hours. Moreover there was little increase in the
amount of metabolite formed in the first 24h following
administration of 1200mgm 2 compared with 800mgm-2
(Figure 6).
Urinary recovery of amphethinile is shown in Table III.
Less than 2% of the administered dose was excreted in the
urine in the first 24h at all dose levels and the metabolite
was not detected in the urine.
HPLC assay
The efficiency of the extraction procedure for amphethinile
was 90% at low concentrations (0.1-10pgml-1) falling to
70% at 100pgml-1 and for the internal standard was 90%.
The inter-assay variation was 5.6%. Amphethinile eluted at
7min, the internal standard at 4min and the metabolite at
2min (Figure 3).
Clinical study
A total of fifteen patients were entered into the study and
their characteristics are shown in Table IV.
The starting dose of 40mgm-2 proved to be entirely non-
toxic and since the AUC was <5% of the target AUC the
second dose level studied was 200mgm-2. Two patients
were treated at this dose. No objective or subjective toxicity
was seen until the first patient received his second course.
During this bolus injection he had a grand mal convulsion
from which he made a full recovery within a few minutes.
There was no past history of epilepsy and no evidence of
brain metastases. There was no suggestion that an acute
drop in blood pressure had occurred with resultant hypoxia.
It was therefore considered that the fit was due to a bolus
effect, possibly a counterpart of the catatonia seen in mice
following rapid i.v. injection and it was decided to admin-
ister future courses as a short infusion rather than a bolus
injection. A further two patients were treated at 400mgm-2
The only subjective toxicity at this dose was a transient
feeling of warmth during the latter part of the infusion. No
objective toxicity was recorded.
The dose was then escalated to 800mgm 2 and 6 patients
were entered at this level. All six patients experienced nausea
+ vomiting and all complained ofmarked lethargy lasting 3-
7 days following treatment. In addition 4/6 patients noted a
feeling of light headedness lasting 15-30min after the end of
the infusion. Two patients developed diarrhoea lasting 2-4
days. Three patients experienced severe pain as a result of
treatment. The first patient had a soft tissue sarcoma with a
mass in the right buttock. Forty minutes after the infusion
ended she developed severe pain in the buttock radiating
down the right leg. The pain required opiate analgesics and
recurred when she was retreated. The second patient with
locally recurrent ovarian carcinoma developed pain in the
abdomen again approximately 1 h after completing treatment
and requiring opiate analgesia. The third patient developed
colicky abdominal pain associated with diarrhoea 12h after
completing therapy. This was not associated with a known site
of disease.
Objective toxicity was seen in only one patient at
800mgm 2. This patient developed a wbc of 1.4 x1091-1
seven days after treatment with recovery by day fourteen
and in addition she developed total alopecia. The AUC for
this patient was 230pg1-1 h-1. Before administering
amphethinile she had rapidly progressive pulmonary metas-
tases from a soft tissue sarcoma and these stabilised for four
months during therapy. This was the only indication of anti-
tumour activity seen during the trial.
The majority of patients (4/6) treated at 800mgm2 had
an AUC less than half the target AUC and therefore a
further 50% escalation to 1200mgm-2 was undertaken. The
first patient treated at this level, a 27 year old man,
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Table II Pharmacokinetic parameters of amphethinile in man
VC VD VSS VPC TJ/2a TJ1/2f AUC Cl
Patient Dose Course KE K2>I KJ<2 1 1 1 1 h h jgl-l h-1 mmlin-l
RH 200 1 0.61 1.49 1.37 62.0 132.6 118.9 56.9 0.21 2.40 9.42 636.5
JC 200 1 2.88 3.38 10.49 10.2 48.9 42.0 31.7 0.04 1.14 11.51 492.3
JC 200 2 0.96 1.42 2.43 27.8 88.3 75.4 47.6 0.15 2.29 12.74 444.6
Mean 1.48 2.09 4.76 33.3 89.9 78.8 45.4 0.13 1.94 11.22 524.5
sem 0.07 0.64 2.00 15.2 24.1 22.2 7.3 0.04 0.4 0.93 57.6
GG 400 1 0.91 6.40 12.29 46.9 141.3 136.9 90.0 0.03 2.29 17.56 711.6
GG 400 2 1.24 2.74 9.23 23.2 109.7 101.4 78.2 0.05 2.63 25.98 481.0
TL 400 1 1.89 2.38 13.66 6.3 47.3 42.9 36.5 0.03 2.71 45.53 201.3
FL 400 2 0.16 0.92 0.58 46.6 79.5 76.0 29.4 0.43 7.00 69.84 131.2
Mean 1.05 3.11 8.94 30.7 94.5 89.3 58.5 0.14 3.66 39.72 381.2
sem 0.35 1.16 2.93 9.8 20.1 19.8 15.0 0.09 1.11 11.62 133.5
MG 800 1 0.25 0.79 0.72 46.3 96.2 88.4 42.1 0.41 5.54 112.1 200.6
FL 800 1 0.12 1.26 0.78 38.1 63.4 61.9 23.7 0.33 9.24 231.1 79.3
FL 800 3 0.11 1.03 1.15 41.9 90.9 88.4 46.5 0.31 13.33 243.2 78.7
JB 800 1 0.24 2.35 1.26 63.1 99.2 96.9 33.7 0.19 4.62 80.6 248.1
NB 800 1 0.14 0.57 0.69 73.1 171.8 161.2 88.1 0.52 11.36 122.1 174.7
AG 800 1 0.10 1.45 1.14 41.5 75.4 74.0 32.5 0.26 12.16 223.3 71.8
SL 800 1 0.15 0.51 0.27 90.9 150.1 139.5 48.6 0.83 7.62 109.7 227.7
Mean 0.16 1.13 0.87 56.4 106.7 101.5 45.0 0.40 9.12 160.3 154.1
sem 0.02 0.24 0.15 7.5 14.9 13.5 7.8 0.08 1.26 26.0 28.9
DM 1200 1 0.09 0.33 0.21 59.9 110.7 103.2 43.2 1.11 13.8 361.1 92.3
GM 1200 1 0.20 5.61 5.41 57.0 112.9 111.9 54.9 0.06 6.9 194.7 188.2
PC 1200 1 0.11 0.45 0.22 137.7 219.3 206.3 68.6 0.98 9.76 154.0 259.5
Mean 0.13 2.13 1.95 84.9 147.7 140.5 55.5 0.71 10.18 236.6 180.0
sem 0.33 1.74 1.72 26.4 35.8 33.0 7.3 0.33 2.01 63.3 48.4
KE: elimination rate constant; K2> 1: rate constant governing transfer from peripheral to central compartment; K2<1: rate constant
governing from central to peripheral compartment; VC: volume of the central compartment; VDarea: volume of distribution at time zero;
VDSS: volume of distribution at steady state; VPC: volume of the peripheral compartment; T1/2a: half life of the a (distribution) phase; Tl/
2,B: half life of the ,B (elimination) phase; AUC: area under the concentration/time curve; Cl: clearance.
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Figure 5 Plasma decay curves of amphethinile in man. Points
represent the mean values of 3 courses at 200mgm-2 (*), 4
courses at 400mgm-2 (+), 7 courses at 800mgm-2 (x) and 3
courses at 1200mgm-2 (0).
Table III Urinary excretion of amphethinile
Dose 24h excretion % dose
Patient mg Course ,ug administered
RH 360 1 192 0.053
JC 340 1 42 0.012
340 2 58 0.017
GG 750 1 471 0.062
750 2 705 0.094
TL 550 1 829 0.150
550 2 491 0.084
MG 1350 1 1350 0.200
FL 1100 1 635 0.050
550 2 734 0.133
JB 1200 1 8407 0.700
NB 1280 1 513 0.040
AG 960 1 709 0.070
GM 2200 1 522 0.020
PC 2400 1 594 0.020
Table IV Patient characteristics
6 8 10 12 14 16 18 20
Time (hours)
Total
Age, median (range)
Sex, M:F
Performance status (WHO) 0
1
2
Tumour types Non-small cell lung cancer
Sarcoma
Ovarian carcinoma
Small cell lung cancer
Colon
Teratoma
Figure 6 Plasma decay curves of amphethinile metabolite in Prior radiotherapy
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experienced severe nausea and vomiting, a feeling of pro-
found lethargy for 7 days, an unusual inability to focus
properly for 4 days and total alopecia. This patient had an
AUC of 361 gI-1h-I and also developed neutropenia of
1.9x 1091-1 at day 14 with recovery by day 21. The next
patient was a 59 year old man with widespread massive
intra-abdominal involvement with soft tissue sarcoma. This
patient also experienced grade 3 nausea and vomiting and
lethargy but two days after treatment was admitted with
abdominal pain, haematemesis and melaena and died 12h
later. A post mortem was not performed. It was considered
that an intra-abdominal catastrophe related to the large
abdominal mass had occurred. A third patient, a 61 year old
man with non-small cell lung cancer, was therefore entered.
This patient had few initial side effects apart from light
headedness for 60min at the end of the infusion and one
episode of vomiting. However 12h later he suffered a right
hemiparesis and died the following day. A post mortem
showed a friable area of atheromatous plaque in the ascend-
ing aorta with emboli in the brain, spleen and both kidneys.
Two deaths therefore occurred at 1200mgm-2 within 48h
of treatment and although these did not conform to the
more usual patterns of drug related death it was considered
that the amphethinile or the solutol vehicle had contributed
significantly to these events. In order to resolve the question
of the possible toxicity of the vehicle, solutol was adminis-
tered as a short infusion diluted in normal saline to two
patients each at doses equal to those in the amphethinile
formulation at 400, 800 and 1200mgm-2 and no toxicity
was seen. It thus seems likely that the side effects that
occurred during this trial were caused by the amphethinile
and thus the trial was terminated.
During the trial one patient had a hypersensitivity reaction
consisting of chest tightness, sweating, nausea and vomiting
following the first course of treatment. These symptoms
recurred with the second course after only 1-2ml had been
infused. The patient made a full recovery.
Discussion
Dose escalation procedures for phase I clinical trials have
always relied on empirical formulae such as the modified
Fibonacci series. These methods tend to be rigid in appli-
cation so that while they arrive at a maximum tolerated dose
for some drugs in an efficient manner for others many
escalation steps are required. In addition the majority of the
patients included in such trials, over 60%, (Estey et al.,
1986) receive doses less than those subsequently recom-
mended for phase II testing. However Collins et al. (1986)
have suggested that pharmacological data can be used to
develop a more rational approach to dose escalation. They
noted a close relationship between the AUC at the LD1O in
the mouse and the AUC at the MTD in man for a number
of drugs and proposed that the AUC at the mouse LD1O
might therefore be used as a target for the phase I clinical
trial. It was suggested that the dose could be escalated
rapidly to a dose that produces an AUC in the range of the
target and then more slowly thereafter to the MTD. Such a
scheme would omit the majority of the early escalation steps
and thus reduce the duration of the trial and the numbers of
patients treated at clearly sub-therapeutic doses.
There are however a number of pitfalls to be avoided
when considering the use of pharmacokinetics data to guide
dose escalation. The comparison of AUCs will compensate
for species differences in drug metabolism, elimination and
binding but takes no account of any inter species differences
in target cell sensitivity or schedule dependency. While some
indication of the latter can be inferred from a comparison of
the daily x 5 and single dose toxicology data, target cell
sensitivity is very difficult to evaluate. However, it appears
that antimetabolites are at high risk of such inter species
target cell differences and are probably not suitable for
pharmacologically guided dose escalation.. Drugs that exhi-
bit non-linear kinetics provide further problems. For such
agents the AUC may rise rapidly with small increments in
dose providing a risk of inadvertent excessive toxicity.
In the phase I trial of amphethinile reported above the
maximum dose was reached after four escalations. If the
modified Fibonacci series had been used the same maximum
dose would have taken 9-10 escalations requiring an addi-
tional 9-12 months work to complete the study. The use of
pharmacological data to guide dose escalation was thus
successful in eliminating the early stages of the trial, reducing
the numbers of patients treated at low doses and signifi-
cantly shortening the duration of the study. In addition the
trial showed that a degree of non-linearity in the kinetics is
not a bar to their use to guide dose escalation if care is
taken.
Unfortunately two deaths occurred at the maximum dose
used in the study. These deaths appeared to result from
vascular causes and in both cases occurred in older patients
who are at risk of pre-existing degenerative vascular disease.
In neither case was systemic drug exposure high (AUC
<200pgI-1 h-1) although it is possible that some combined
effect of the amphethinile+solutol was responsible for the
effects. This demonstrates another problem with dose escala-
tion based on pharmacological data. Such data cannot
predict when toxic effects will occur that are not related to
AUC and argues for caution in the later stages of trials.
However highly unpredictable effects cannot be forseen by
any method and are one of the inherent risks of phase I
studies.
A further difficulty with this trial was that the formulation
vehicle, solutol, had not been previously used in man. This
raises the question of when such agents should be tested in
man. Most patients enter phase I trials because they believe
there is a chance that the treatment may help them. Would
they be prepared to receive doses of a vehicle that had no
likelihood of any effect on their disease? Logically solubilis-
ing agents should be tested prior to their inclusion in a
formulation in order to avoid waste of resources if the agent
proved to have unwanted biological effects. For solutol there
was good scientific and animal data to suggest that it was
considerably safer than the related Cremophor EL and thus
a compromise design was used in this study where the
solutol alone and the formulated drug were tested
concurrently.
We believe that this trial demonstrates the potential for
pharmacologically based dose escalation schemes in reducing
the time and numbers of patients required for phase I trials.
In addition a higher proportion of patients may be treated at
potentially therapeutic doses. The trial also underlines the
care that must be taken at higher doses irrespective of the
dose escalation method in use.
Due to the occurrence of unpredictable neurological and
vascular toxicities it was not possible to administer a dose of
amphethinile that could achieve consistent cytotoxic effects
in terms of neutropenia and alopecia. For this reason the
drug cannot be recommended for phase II testing by the i.v.
route. However amphethinile remains an interesting com-
pound and future trials are planned using an oral
formulation.
This work was supported by the Cancer Research Campaign.
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